A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD

Trial Profile

A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms telos
  • Sponsors AstraZeneca AB; Pearl Therapeutics
  • Most Recent Events

    • 21 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 09 Feb 2018 This trial was completed Czech Republic (end date: 2017-12-01), according to European Clinical Trials Database.
    • 15 Jan 2018 This trial was completed in Poland (end date: 2017-12-01), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top